CAPTRUST Financial Advisors
NYMX

CAPTRUST Financial Advisors’s Nymox Pharmaceutical Corp NYMX Stock Holding History

CAPTRUST Financial Advisors’s Portfolio NYMX Stock Details NYMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-200
Closed – – 4434
2022
Q2 		$0 Hold
200
– – ﹤0.01% 5233
2022
Q1 		$0 Hold
200
– – ﹤0.01% 5234
2021
Q4 		$0 Buy
+200
New +$319 ﹤0.01% 4999

Other funds holding NYMX

FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
LSA
Leonteq Securities AG Zurich, Switzerland $2.7B AUM 31.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GG
Gofen & Glossberg Chicago, Illinois $3.89B AUM 11.97% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
FCFC
First Citizens Financial Corp Mason City, Iowa $239M AUM 26.56% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

CAPTRUST Financial Advisors's NYMX Position: Q3 2022 in Review

CAPTRUST Financial Advisors sold out of Nymox Pharmaceutical Corp (NYMX) in Q3 2022, closing a stake of 200 shares.

CAPTRUST Financial Advisors first reported a position in NYMX in Q4 2021 and held it in 3 quarters. The position peaked at $0 in Q2 2022. 34 funds tracked by Wall St. Rank hold NYMX as of Q3 2022.

  • CAPTRUST Financial Advisors reported no remaining Nymox Pharmaceutical Corp position as of Q3 2022 after selling out during the quarter.
  • CAPTRUST Financial Advisors sold 200 Nymox Pharmaceutical Corp shares in Q3 2022.
  • CAPTRUST Financial Advisors first reported a position in Nymox Pharmaceutical Corp in Q4 2021 and held it in 3 quarters.
  • CAPTRUST Financial Advisors's Nymox Pharmaceutical Corp position peaked at $0 in Q2 2022.
  • 34 funds tracked by Wall St. Rank held Nymox Pharmaceutical Corp as of Q3 2022.

Based on CAPTRUST Financial Advisors's 13F filing for Q3 2022, filed 16 Nov 2022.